Benzinga - by Benzinga Insights, Benzinga Staff Writer.
On March 6, a recent SEC filing unveiled that GTCR INVESTMENT XI LLC, Director at Sotera Health (NASDAQ:SHC) made an insider sell.
What Happened: LLC's recent move involves selling 11,062,908 shares of Sotera Health. This information is documented in a Form 4 filing with the U.S. Securities and Exchange Commission on Wednesday. The total value is $158,282,556.
Sotera Health's shares are actively trading at $14.24, experiencing a up of 0.07% during Thursday's morning session.
Discovering Sotera Health: A Closer Look Sotera Health Co provides sterilization, analytical lab testing, and advisory services to help ensure that medical, pharmaceutical and food products are safe for healthcare practitioners, patients, and consumers. The company operates in three segments: Sterigenics, Nordion, and Nelson Labs. Sterigenics provides outsourced terminal sterilization and irradiation services for medical device, pharmaceutical, food safety, and advanced applications; Nordion provides Co-60 and gamma irradiators, which are the key components to the gamma sterilization process; and Nelson Labs provides outsourced microbiological and analytical chemistry testing for the medical device and pharmaceutical industries. Its geographical segments are the United States, Canada, Europe, and other regions.
Breaking Down Sotera Health's Financial Performance Positive Revenue Trend: Examining Sotera Health's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 23.31% as of 31 December, 2023, showcasing a substantial increase in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Holistic Profitability Examination:
- Gross Margin: Achieving a high gross margin of 58.05%, the company performs well in terms of cost management and profitability within its sector.
- Earnings per Share (EPS): Sotera Health's EPS lags behind the industry average, indicating concerns and potential challenges with a current EPS of 0.14.
Valuation Overview:
- Price to Earnings (P/E) Ratio: With a higher-than-average P/E ratio of 79.06, Sotera Health's stock is perceived as being overvalued in the market.
- Price to Sales (P/S) Ratio: The P/S ratio of 3.84 is lower than the industry average, implying a discounted valuation for Sotera Health's stock in relation to sales performance.
- EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation & Amortization): With an EV/EBITDA ratio lower than industry averages at 14.88, Sotera Health could be considered undervalued.
Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.
The Relevance of Insider Transactions Insider transactions, although significant, should be considered within the larger context of market analysis and trends.
Within the legal framework, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities as per Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are mandated to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
The initiation of a new purchase by a company insider serves as a strong indication that they expect the stock to rise.
However, insider sells may not always signal a bearish view and can be influenced by various factors.
Exploring Key Transaction Codes Delving into transactions, investors typically prioritize those unfolding in the open market, as precisely outlined in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
Check Out The Full List Of Sotera Health's Insider Trades.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.